Every Hayes clinical evidence report is developed by experienced teams that have been trusted by healthcare decision makers since 1989. Here is a sampling of our content that is being used every day to inform defensible, evidence-based decisions by payers and providers.
Not all reports are available for public preview. For more information, please contact us.
Avacopan is an oral complement component 5a (C5a) antagonist for treatment of adult patients with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV).
This report evaluates the clinical utility of cell-free DNA (cfDNA) (formerly NIPS, NIPT) screening for fetal trisomy 21, 18, and 13 in women with twin pregnancies.
This report evaluates the clinical utility of genetic testing to detect hereditary cancer 1) high risk and 2) moderate risk gene variants in women with new diagnoses of breast cancer (BC), who are not preselected for other risk factors, to improve disease management.
Teplizumab is an intravenously administered anti-CD3 monoclonal antibody in development for the delay of clinical type 1 diabetes (T1D) in at-risk individuals.
The Port Delivery System (PDS) with ranibizumab is an investigational intraocular, refillable reservoir implant filled with ranibizumab for the treatment of neovascular age-related macular degeneration.
Focus of the Report: This report focuses on the use of radiofrequency ablation (RFA) for treatment of symptomatic benign thyroid nodules (BTNs) in adult patients.
Technology Description: RFA is an ultrasound (US)-guided, minimally invasive treatment approach, which applies high frequen…
Focus of the Report: This report focuses on annular closure for the prevention of recurrent lumbar disc herniation (LDH) after lumbar discectomy (LD).
Technology Description: Annular closure is a surgical treatment that is performed immediately following an LDH debridement surgery (e.g., l…
RBX2660 is a microbiota-based investigational product for fecal microbiota transplantation proposed to treat recurrent Clostridium difficile infection. It is derived from fresh stool from multiple donors; both donors and stool samples are methodically screened. Pooled stool samples are commercially prepared under good manufacturing processes. RB…
Ryplazim is plasma-derived human plasminogen indicated for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia). Ryplazim is recovered from healthy donor plasma; plasminogen is extracted using a proprietary process. Purified isolated plasminogen is administered by intravenous infusion.
Lumakras (sotorasib) is an oral KRAS G12C inhibitor designed to block the abnormal proliferative action of mutant KRAS protein. It is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who hav…